http://www.chicagotribune.com/news/local/ct-x-1010-expert-kozloff-20121010,0,1846507.story
Ingalls is one of a handful of Illinois hospitals participating in a large-scale clinical trial to determine whether a common and inexpensive diabetes drug, metformin, may be the next new weapon in the fight against breast cancer.
Findings from the five-year study, sponsored by the National Cancer Institute, could be available in 2016, according to Bloomberg News.
See also:
http://www.gastroendonews.com/ViewA...s&d_id=481&i=October+2012&i_id=889&a_id=21837
Results from an American case–control study and a nationwide study from Taiwan showed HCC incidence plummeted in patients with diabetes who were taking metformin compared with diabetic patients who were not receiving the therapy.
“The results are astonishing. If you put it together, these two papers, we have potentially a breakthrough in the prevention of liver cancer,” said Jacques Devière, MD, PhD, professor of medicine at Erasme University Hospital in Brussels, Belgium, after hearing the studies presented.
Previous epidemiologic studies have suggested that metformin may be protective against many cancers, and a recent study published in Cancer Prevention Research showed that metformin slowed tumor activity in mice given chemically-induced liver tumors (Bhalla K et al. 2012;5:544–552).
Ingalls is one of a handful of Illinois hospitals participating in a large-scale clinical trial to determine whether a common and inexpensive diabetes drug, metformin, may be the next new weapon in the fight against breast cancer.
Findings from the five-year study, sponsored by the National Cancer Institute, could be available in 2016, according to Bloomberg News.
See also:
http://www.gastroendonews.com/ViewA...s&d_id=481&i=October+2012&i_id=889&a_id=21837
Results from an American case–control study and a nationwide study from Taiwan showed HCC incidence plummeted in patients with diabetes who were taking metformin compared with diabetic patients who were not receiving the therapy.
“The results are astonishing. If you put it together, these two papers, we have potentially a breakthrough in the prevention of liver cancer,” said Jacques Devière, MD, PhD, professor of medicine at Erasme University Hospital in Brussels, Belgium, after hearing the studies presented.
Previous epidemiologic studies have suggested that metformin may be protective against many cancers, and a recent study published in Cancer Prevention Research showed that metformin slowed tumor activity in mice given chemically-induced liver tumors (Bhalla K et al. 2012;5:544–552).
